Lanthanum carbonate

Drug Profile

Lanthanum carbonate

Alternative Names: Bay 771931; Fosrenol; Foznol; Lambda; SPD405

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Bayer Yakuhin; Shire
  • Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 31 Jan 2018 Lanthanum carbonate is still in phase II trials for Hyperphosphataemia (In adolescents, In children, In infants, Late-stage disease) in Argentina, Bulgaria, Chile, Czech Republic, Germany, Hungary, Poland, Romania, Russia, South Africa, and Turkey (NCT01696279)
  • 30 Nov 2015 Launched for Hyperphosphataemia (Late-stage disease) in USA before November 2015 (PO)
  • 27 Apr 2015 The product is still in phase-II for Hyperphosphataemia (in children) in Germany and Hungary
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top